PT713495E - Metodos de aumento da bioactividade de quimocinas - Google Patents

Metodos de aumento da bioactividade de quimocinas

Info

Publication number
PT713495E
PT713495E PT94920701T PT94920701T PT713495E PT 713495 E PT713495 E PT 713495E PT 94920701 T PT94920701 T PT 94920701T PT 94920701 T PT94920701 T PT 94920701T PT 713495 E PT713495 E PT 713495E
Authority
PT
Portugal
Prior art keywords
methods
bioactivity
increased chemical
truncated
binding
Prior art date
Application number
PT94920701T
Other languages
English (en)
Inventor
Pradip Kumar Bhatnagar
Louis M Pelus
Andrew Garrison King
Joanna Maria Balcarek
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PT713495E publication Critical patent/PT713495E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT94920701T 1993-06-08 1994-06-03 Metodos de aumento da bioactividade de quimocinas PT713495E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7380093A 1993-06-08 1993-06-08

Publications (1)

Publication Number Publication Date
PT713495E true PT713495E (pt) 2004-03-31

Family

ID=22115875

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94920701T PT713495E (pt) 1993-06-08 1994-06-03 Metodos de aumento da bioactividade de quimocinas

Country Status (9)

Country Link
US (3) US6080398A (pt)
EP (2) EP1378522A3 (pt)
JP (1) JP4006021B2 (pt)
AT (1) ATE253637T1 (pt)
DE (1) DE69433301T2 (pt)
DK (1) DK0713495T3 (pt)
ES (1) ES2210255T3 (pt)
PT (1) PT713495E (pt)
WO (1) WO1994029341A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
PT713495E (pt) * 1993-06-08 2004-03-31 Smithkline Beecham Corp Metodos de aumento da bioactividade de quimocinas
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
AT403098B (de) * 1995-05-29 1997-11-25 Nycomed Austria Gmbh Antikörper zum nachweis und zur unterscheidung von verkürzten und nicht verkürzten formen von chemokinen
ZA968896B (en) * 1995-10-24 1997-04-24 Smithkline Beecham Corp Method of mobilizing hematopoietic stem cells
JP2000504310A (ja) * 1995-11-21 2000-04-11 スミスクライン・ビーチャム・コーポレイション 敗血症の治療方法
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
AU1616499A (en) * 1997-12-01 1999-06-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chemokine variants and methods of use
AU2002216749A1 (en) * 2000-06-30 2002-01-14 Smithkline Beecham Corporation Chemokine conjugates
EP1732942A4 (en) * 2004-03-30 2008-12-03 Amylin Pharmaceuticals Inc SYNTHETIC CHEMOKINES, MANUFACTURING METHODS AND APPLICATIONS
CN101094684A (zh) * 2004-08-13 2007-12-26 阿诺麦德股份有限公司 用趋化因子的组合活化祖细胞/干细胞
US20100144641A1 (en) * 2005-09-12 2010-06-10 Popel Aleksander S Compositions Having Antiangiogenic Activity and Uses Thereof
WO2008017025A2 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
CN101500595A (zh) * 2006-08-07 2009-08-05 健赞股份有限公司 组合治疗
EP2499242B1 (en) 2009-11-15 2019-05-01 Indiana University Research&technology Corporation Methods to enhance delivery and engraftment of stem cells including the identification of specific prostagandin e2 receptors
SG11201508027PA (en) 2013-02-28 2015-11-27 Harvard College Methods and compositions for mobilizing stem cells
CN110785419B (zh) 2017-04-12 2024-03-01 博雅缉因（北京）生物科技有限公司 芳烃受体拮抗剂及其用途
US11267881B2 (en) * 2017-09-14 2022-03-08 Charles ROSSER Compositions and methods for treatment of diseases involving CXCL1 function
WO2019089826A1 (en) 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
CN111683669A (zh) 2017-10-31 2020-09-18 美真达治疗公司 用于造血干细胞和祖细胞移植疗法的组合物和方法
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
KR20200096942A (ko) 2017-12-06 2020-08-14 마젠타 테라퓨틱스 인코포레이티드 조혈 줄기 및 자손 세포의 동원을 위한 투여 요법
AU2019205262A1 (en) 2018-01-03 2020-07-23 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20220401481A1 (en) 2019-11-01 2022-12-22 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20230330185A1 (en) 2020-04-27 2023-10-19 Magenta Therapeutics, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703206A (en) * 1981-09-08 1997-12-30 Univ Rockefeller Macrophage inflammatory protein 2 (MIP-2)
GB8626539D0 (en) * 1986-11-06 1986-12-10 Nycomed As Peptide compounds
ZW11290A1 (en) * 1989-07-14 1990-10-31 Smithkline Beecham Corp Hemoregulatory peptides
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
PT98072B (pt) * 1990-06-22 1998-11-30 Chiron Corp Processo para a preparacao de polipeptidos contendo proteina macrofagica inflamatoria humana mip-2 alfa por metodos recombinantes e de composicoes farmaceuticas que os contem
US5154921A (en) * 1990-07-13 1992-10-13 Dana-Farber Cancer Institute, Inc. Promotion of maturation of hematopoietic progenitor cells
CA2092924A1 (en) * 1990-09-28 1992-03-29 John Stephen Haskill Gro genes, proteins, and uses thereof
PT713495E (pt) * 1993-06-08 2004-03-31 Smithkline Beecham Corp Metodos de aumento da bioactividade de quimocinas
ES2172536T3 (es) * 1993-06-15 2002-10-01 British Biotech Pharm Liberacion y movilizacion de celulas hematopoyeticas.
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
US5459128A (en) * 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
GB9426012D0 (en) * 1994-12-22 1995-02-22 British Biotech Pharm Mobilisation of haematopoietic cells

Also Published As

Publication number Publication date
ES2210255T3 (es) 2004-07-01
DE69433301T2 (de) 2004-09-09
EP0713495A4 (en) 1998-06-03
EP0713495B1 (en) 2003-11-05
US20040057925A1 (en) 2004-03-25
US6080398A (en) 2000-06-27
DE69433301D1 (de) 2003-12-11
JPH08511167A (ja) 1996-11-26
JP4006021B2 (ja) 2007-11-14
EP0713495A1 (en) 1996-05-29
DK0713495T3 (da) 2004-03-08
EP1378522A2 (en) 2004-01-07
ATE253637T1 (de) 2003-11-15
US6399053B1 (en) 2002-06-04
WO1994029341A1 (en) 1994-12-22
EP1378522A3 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
PT713495E (pt) Metodos de aumento da bioactividade de quimocinas
FR2715847B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
NO885275L (no) Vaskulaere antikoagulantproteiner, dna'er som koder for dem, fremstilling og anvendelse derav.
NO910796L (no) Forbedrede biologiske insektkontrollmidler og fremgangsmaater ved bruk derav.
DE69021529T2 (de) Reaktionsgefäss.
ATE342911T1 (de) Synthese von nukleosiden und polynukleotiden
ES2055234T3 (es) Agente con contenido de anticoagulante.
DE3870959D1 (de) 2-difluormethoxy-1,1,1,2-tetrafluoraethan als anaesthetikum.
DE69000828D1 (de) Sauerstoffsorbentmittel.
CA2008817A1 (en) M-csf monoclonal antibodies that recognize a neutralizing conformational epitope
FR2659658B1 (fr) Silice traitee par un organosilicone et composition la contenant.
NO167376C (no) Flertrinns biologisk renseanlegg.
ATE92542T1 (de) Azeotropaehnliche zusammensetzungen von 1,1dichlor-2,2,2-trifluoraethan und 1,1-dochlor-1fluor|than.
FR2714062B1 (fr) Promoteur modifié pour ARN polymérase, sa préparation et ses applications.
DE69231940T2 (de) Rekombinant DNS kodierend für eine Endochitinase
ATE271125T1 (de) Neuartige tyrosinkinase
DE68910676D1 (de) Verwendung von Creosot als antispastischer Wirkstoff.
MX9203684A (es) Benzotiazepinas.
DE69421665D1 (de) Anomere Fluorribosylamine
ITBZ930026A0 (it) Procedimento per la movimentazione traslatoria di componenti ed azio- natore di movimento per l'attuazione del procedimento.
ATE75316T1 (de) Membran-affinitaet-konzentrationsimmuntest.
NO890035D0 (no) Colepteran-aktive mikroorganismer, relaterte insekticid-sammensetninger og fremgangsmaater og anvendelse derav.
ES1012325Y (es) Estructura de viga.
TR27159A (tr) Sübstitüe edilmis 2 -fenil-5-(3-fenoksifelin (1,1,1-trifloropentanlari hazirlamaya mahsus yöntem ve aramaddeler.
ES267893Y (es) "contenedor-conservador de vinos embotellados".